Array BioPharma analyst commentary at Piper JaffrayPiper raises U.S. sales forecast for Array based on 'strong' quarter, Rx trends. Piper Jaffray analyst Edward Tenthoff noted that Array Biopharma (ARRY) reported Q2 MEKTOVI and BRAFTOVI sales of $22.7M that beat his and the consensus forecast. Management "importantly" commented that doctors are switching patients from Novartis' (NVS) doublet Mekinist + Tafinlar, said Tenthoff, who also noted that total prescriptions doubled to 2,600 from 1,300 in the first quarter of launch. Following the report and call, Tenthoff raised his U.S. sales forecast for calendar 2019 to $117M and keeps an Overweight rating on Array shares with a $28 price target.Read more at: (source)https://thefly.com/landingPage...* This stock has been on our trading list for a while now. Will continue to look for trades in this name. * $ARRY, Array BioPharma Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.